Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Performance of the Gail and Tyrer-Cuzick breast cancer risk assessment models in women screened in a primary care setting with the FHS-7 questionnaire.

Vianna FSL, Giacomazzi J, Oliveira Netto CB, Nunes LN, Caleffi M, Ashton-Prolla P, Camey SA.

Genet Mol Biol. 2019;42(1 suppl 1):232-237. doi: 10.1590/1678-4685-GMB-2018-0110. Epub 2019 Jun 3.

2.

Body image (dis)satisfaction among low-income adult women.

Kops NL, Bessel M, Knauth DR, Caleffi M, Wendland EM.

Clin Nutr. 2019 Jun;38(3):1317-1323. doi: 10.1016/j.clnu.2018.05.022. Epub 2018 Jun 13.

PMID:
29934132
3.

Body Weight and Breast Cancer: Nested Case-Control Study in Southern Brazil.

Kops NL, Bessel M, Caleffi M, Ribeiro RA, Wendland EM.

Clin Breast Cancer. 2018 Oct;18(5):e797-e803. doi: 10.1016/j.clbc.2018.04.014. Epub 2018 Apr 28.

PMID:
29778786
4.

Filling the Gap in Extended Metal Atom Chains: Ferromagnetic Interactions in a Tetrairon(II) String Supported by Oligo-α-pyridylamido Ligands.

Nicolini A, Galavotti R, Barra AL, Borsari M, Caleffi M, Luo G, Novitchi G, Park K, Ranieri A, Rigamonti L, Roncaglia F, Train C, Cornia A.

Inorg Chem. 2018 May 7;57(9):5438-5448. doi: 10.1021/acs.inorgchem.8b00405. Epub 2018 Apr 18.

PMID:
29668273
5.

Assessment of potential risk factors for breast cancer in a population in Southern Brazil.

Breyer JZ, Wendland EM, Kops NL, Caleffi M, Hammes LS.

Breast Cancer Res Treat. 2018 May;169(1):125-131. doi: 10.1007/s10549-017-4655-0. Epub 2018 Jan 17.

PMID:
29344741
6.

p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers.

Macedo GS, Vieira IA, Vianna FSL, Alemar B, Giacomazzi J, Brandalize APC, Caleffi M, Volc SM, de Campos Reis Galvão H, Palmero EI, Achatz MI, Ashton-Prolla P.

Fam Cancer. 2018 Apr;17(2):269-274. doi: 10.1007/s10689-017-0028-4.

PMID:
28756477
7.

Estimation of Premature Deaths From Lack of Access to Anti-HER2 Therapy for Advanced Breast Cancer in the Brazilian Public Health System.

Debiasi M, Reinert T, Kaliks R, Amorim G, Caleffi M, Sampaio C, Fernandes GDS, Barrios CH.

J Glob Oncol. 2016 Jul 20;3(3):201-207. doi: 10.1200/JGO.2016.005678. eCollection 2017 Jun.

8.

Screening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from Southern Brazil.

Palmero EI, Alemar B, Schüler-Faccini L, Hainaut P, Moreira-Filho CA, Ewald IP, Santos PK, Ribeiro PL, Oliveira CB, Calvez-Kelm FL, Tavtigian S, Cossio SL, Giugliani R, Caleffi M, Ashton-Prolla P.

Genet Mol Biol. 2016 May 24;39(2):210-22. doi: 10.1590/1678-4685-GMB-2014-0363. Erratum in: Genet Mol Biol. 2017 Mar 16;:0.

9.

On the Probabilistic Deployment of Smart Grid Networks in TV White Space.

Cacciapuoti AS, Caleffi M, Paura L.

Sensors (Basel). 2016 May 10;16(5). pii: E671. doi: 10.3390/s16050671.

10.

On the Achievable Throughput Over TVWS Sensor Networks.

Caleffi M, Cacciapuoti AS.

Sensors (Basel). 2016 Mar 30;16(4):457. doi: 10.3390/s16040457.

11.

Rare germline variant (rs78378222) in the TP53 3' UTR: Evidence for a new mechanism of cancer predisposition in Li-Fraumeni syndrome.

Macedo GS, Araujo Vieira I, Brandalize AP, Giacomazzi J, Inez Palmero E, Volc S, Rodrigues Paixão-Côrtes V, Caleffi M, Silva Alves M, Achatz MI, Hainaut P, Ashton-Prolla P.

Cancer Genet. 2016 Mar;209(3):97-106. doi: 10.1016/j.cancergen.2015.12.012. Epub 2016 Jan 7.

PMID:
26823150
12.

A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.

Rimawi MF, Aleixo SB, Rozas AA, Nunes de Matos Neto J, Caleffi M, Figueira AC, Souza SC, Reiriz AB, Gutierrez C, Arantes H, Uttenreuther-Fischer MM, Solca F, Osborne CK.

Clin Breast Cancer. 2015 Apr;15(2):101-9. doi: 10.1016/j.clbc.2014.11.004. Epub 2014 Nov 15.

PMID:
25537159
13.

A DNA repair variant in POLQ (c.-1060A > G) is associated to hereditary breast cancer patients: a case-control study.

Brandalize AP, Schüler-Faccini L, Hoffmann JS, Caleffi M, Cazaux C, Ashton-Prolla P.

BMC Cancer. 2014 Nov 19;14:850. doi: 10.1186/1471-2407-14-850.

14.

[Cost-effectiveness of an organized breast cancer screening program in Southern Brazil].

Ribeiro RA, Caleffi M, Polanczyk CA.

Cad Saude Publica. 2013 Nov;29 Suppl 1:S131-45. Portuguese.

15.

Apolipoprotein E genetic polymorphism, serum lipoprotein levels and breast cancer risk: A case-control study.

Cibeira GH, Giacomazzi J, Aguiar E, Schneider S, Ettrich B, DE Souza CI, Camey S, Caleffi M, Weber B, Ashton-Prolla P, Moriguchi EH.

Mol Clin Oncol. 2014 Nov;2(6):1009-1015. Epub 2014 Aug 1.

16.

Prevalence of the TP53 p.R337H mutation in breast cancer patients in Brazil.

Giacomazzi J, Graudenz MS, Osorio CA, Koehler-Santos P, Palmero EI, Zagonel-Oliveira M, Michelli RA, Scapulatempo Neto C, Fernandes GC, Achatz MI, Martel-Planche G, Soares FA, Caleffi M, Goldim JR, Hainaut P, Camey SA, Ashton-Prolla P.

PLoS One. 2014 Jun 17;9(6):e99893. doi: 10.1371/journal.pone.0099893. eCollection 2014.

17.

[Alcohol consumption, social and economic factors and excess weight: a cross-sectional study].

Cibeira GH, Muller C, Lazzaretti R, Nader GA, Caleffi M.

Cien Saude Colet. 2013 Dec;18(12):3577-84. Portuguese.

18.

Association of adipokines and adhesion molecules with indicators of obesity in women undergoing mammography screening.

Isoppo de Souza C, Rosa DD, Ettrich B, Cibeira GH, Giacomazzi J, Tusset P, Ashton-Prolla P, Medeiros LR, Caleffi M, Neto EC, Moriguchi EH, Graudenz MS.

Nutr Metab (Lond). 2012 Oct 31;9(1):97. doi: 10.1186/1743-7075-9-97.

19.

GSTM1, GSTT1, and GSTP1 polymorphisms, breast cancer risk factors and mammographic density in women submitted to breast cancer screening.

de Aguiar ES, Giacomazzi J, Schmidt AV, Bock H, Saraiva-Pereira ML, Schuler-Faccini L, Duarte Filho D, dos Santos PA, Giugliani R, Caleffi M, Camey SA, Ashton-Prolla P.

Rev Bras Epidemiol. 2012 Jun;15(2):246-55.

20.

Prevalence of ERα-397 PvuII C/T, ERα-351 XbaI A/G and PGR PROGINS polymorphisms in Brazilian breast cancer-unaffected women.

Giacomazzi J, Aguiar E, Palmero EI, Schmidt AV, Skonieski G, Filho DD, Bock H, Saraiva-Pereira ML, Ewald IP, Schuler-Faccini L, Camey SA, Caleffi M, Giugliani R, Ashton-Prolla P.

Braz J Med Biol Res. 2012 Oct;45(10):891-7. Epub 2012 May 17.

21.

Prevalence of the BRCA1 founder mutation c.5266dupin Brazilian individuals at-risk for the hereditary breast and ovarian cancer syndrome.

Ewald IP, Izetti P, Vargas FR, Moreira MA, Moreira AS, Moreira-Filho CA, Cunha DR, Hamaguchi S, Camey SA, Schmidt A, Caleffi M, Koehler-Santos P, Giugliani R, Ashton-Prolla P.

Hered Cancer Clin Pract. 2011 Dec 20;9:12. doi: 10.1186/1897-4287-9-12.

22.

Prevalence of the STK15 F31I polymorphism and its relationship with mammographic density.

Giacomazzi J, Aguiar E, Palmero EI, Schmidt AV, Skonieski G, Duarte Filho D, Bock H, Saraiva-Pereira ML, Schuler-Faccini L, Camey SA, Caleffi M, Giugliani R, Ashton-Prolla P.

Braz J Med Biol Res. 2011 Apr;44(4):291-6. Epub 2011 Mar 11.

23.

Breast cancer management in middle-resource countries (MRCs): consensus statement from the Breast Health Global Initiative.

Yip CH, Cazap E, Anderson BO, Bright KL, Caleffi M, Cardoso F, Elzawawy AM, Harford JB, Krygier GD, Masood S, Murillo R, Muse IM, Otero IV, Passman LJ, Santini LA, da Silva RC, Thomas DB, Torres S, Zheng Y, Khaled HM.

Breast. 2011 Apr;20 Suppl 2:S12-9. doi: 10.1016/j.breast.2011.02.015.

PMID:
21388811
24.

The role of breast cancer civil society in different resource settings.

Azenha G, Bass LP, Caleffi M, Smith R, Pretorius L, Durstine A, Perez CP.

Breast. 2011 Apr;20 Suppl 2:S81-7. doi: 10.1016/j.breast.2011.02.005. Epub 2011 Feb 22.

PMID:
21345677
25.

Adherence to a breast cancer screening program and its predictors in underserved women in southern Brazil.

Caleffi M, Ribeiro RA, Bedin AJ Jr, Viegas-Butzke JM, Baldisserotto FD, Skonieski GP, Giacomazzi J, Camey SA, Ashton-Prolla P.

Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2673-9. doi: 10.1158/1055-9965.EPI-10-0338. Epub 2010 Aug 17.

26.

Development and validation of a simple questionnaire for the identification of hereditary breast cancer in primary care.

Ashton-Prolla P, Giacomazzi J, Schmidt AV, Roth FL, Palmero EI, Kalakun L, Aguiar ES, Moreira SM, Batassini E, Belo-Reyes V, Schuler-Faccini L, Giugliani R, Caleffi M, Camey SA.

BMC Cancer. 2009 Aug 14;9:283. doi: 10.1186/1471-2407-9-283.

27.

Population prevalence of hereditary breast cancer phenotypes and implementation of a genetic cancer risk assessment program in southern Brazil.

Palmero EI, Caleffi M, Schüler-Faccini L, Roth FL, Kalakun L, Netto CB, Skonieski G, Giacomazzi J, Weber B, Giugliani R, Camey SA, Ashton-Prolla P.

Genet Mol Biol. 2009 Jul;32(3):447-55. doi: 10.1590/S1415-47572009005000058. Epub 2009 Sep 1.

28.

A model to optimize public health care and downstage breast cancer in limited-resource populations in southern Brazil. (Porto Alegre Breast Health Intervention Cohort).

Caleffi M, Ribeiro RA, Duarte Filho DL, Ashton-Prolla P, Bedin AJ Jr, Skonieski GP, Zignani JM, Giacomazzi J, Franco LR, Graudenz M, Pohlmann P, Fernandes JG, Kivitz P, Weber B.

BMC Public Health. 2009 Mar 13;9:83. doi: 10.1186/1471-2458-9-83.

29.

Consistency of self-reported first-degree family history of cancer in a population-based study.

Roth FL, Camey SA, Caleffi M, Schuler-Faccini L, Palmero EI, Bochi C, Moreira SM, Kalakun L, Giugliani R, Ashton-Prolla P.

Fam Cancer. 2009;8(3):195-202. doi: 10.1007/s10689-008-9228-2. Epub 2009 Jan 20.

PMID:
19153822
30.

Polybrominated diphenyl ethers and polychlorinated biphenyls in human breast adipose samples from Brazil.

Kalantzi OI, Brown FR, Caleffi M, Goth-Goldstein R, Petreas M.

Environ Int. 2009 Jan;35(1):113-7. doi: 10.1016/j.envint.2008.09.008. Epub 2008 Oct 25.

PMID:
18952285
31.

Founder effect of the BRCA1 5382insC mutation in Brazilian patients with hereditary breast ovary cancer syndrome.

da Costa EC, Vargas FR, Moreira AS, Lourenço JJ, Caleffi M, Ashton-Prolla P, Martins Moreira MA.

Cancer Genet Cytogenet. 2008 Jul;184(1):62-6. doi: 10.1016/j.cancergencyto.2008.03.011.

PMID:
18558292
32.

Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil.

Palmero EI, Schüler-Faccini L, Caleffi M, Achatz MI, Olivier M, Martel-Planche G, Marcel V, Aguiar E, Giacomazzi J, Ewald IP, Giugliani R, Hainaut P, Ashton-Prolla P.

Cancer Lett. 2008 Mar 8;261(1):21-5. doi: 10.1016/j.canlet.2007.10.044. Epub 2008 Jan 11.

PMID:
18248785
33.

Clinical characterization and risk profile of individuals seeking genetic counseling for hereditary breast cancer in Brazil.

Palmero EI, Ashton-Prolla P, da Rocha JC, Vargas FR, Kalakun L, Blom MB, Azevedo SJ, Caleffi M, Giugliani R, Schüler-Faccini L.

J Genet Couns. 2007 Jun;16(3):363-71. Epub 2007 Feb 23.

PMID:
17318454
34.

Breast cancer in limited-resource countries: early detection and access to care.

Smith RA, Caleffi M, Albert US, Chen TH, Duffy SW, Franceschi D, Nyström L; Global Summit Early Detection and Access to Care Panel.

Breast J. 2006 Jan-Feb;12 Suppl 1:S16-26.

PMID:
16430395
35.

Reducing the global breast cancer burden: the importance of patterns of care research.

Albain KS, de la Garza Salazar J, Pienkowski T, Aapro M, Bergh J, Caleffi M, Coleman R, Eiermann W, Icli F, Pegram M, Piccart M, Snyder R, Toi M, Hortobagyi GN.

Clin Breast Cancer. 2005 Dec;6(5):412-20. Review.

PMID:
16381624
36.

Cryoablation of benign breast tumors: evolution of technique and technology.

Caleffi M, Filho DD, Borghetti K, Graudenz M, Littrup PJ, Freeman-Gibb LA, Zannis VJ, Schultz MJ, Kaufman CS, Francescatti D, Smith JS, Simmons R, Bailey L, Henry CA, Stocks LH.

Breast. 2004 Oct;13(5):397-407.

PMID:
15454195
37.

Evidence for an association of human papillomavirus and breast carcinomas.

Damin AP, Karam R, Zettler CG, Caleffi M, Alexandre CO.

Breast Cancer Res Treat. 2004 Mar;84(2):131-7.

PMID:
14999143
38.

A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer.

Schwartsmann G, Mans DR, Menke CH, Xavier N, Caleffi M, Ferreira Filho AF, Schunemann H, Kalakun L, Koya R, Pohlman P, Venegas LF.

Oncology (Williston Park). 1997 Apr;11(4 Suppl 3):24-9.

39.

p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment.

Caleffi M, Teague MW, Jensen RA, Vnencak-Jones CL, Dupont WD, Parl FF.

Cancer. 1994 Apr 15;73(8):2147-56.

PMID:
8156519
40.

Tamoxifen protects against steroid-induced bone loss.

Fentiman IS, Saad Z, Caleffi M, Chaudary MA, Fogelman I.

Eur J Cancer. 1992;28(2-3):684-5.

PMID:
1591093
41.

Steroid hormones in lymph and blood from women with early breast cancer.

Hamed H, Caleffi M, Fentiman IS, Thomas B, Bulbrook RD.

Eur J Cancer. 1991;27(1):42-4.

PMID:
1826439
42.

LHRH analogue for treatment of recurrent and refractory mastalgia.

Hamed H, Caleffi M, Chaudary MA, Fentiman IS.

Ann R Coll Surg Engl. 1990 Jul;72(4):221-4.

43.

Premenopausal bone loss in the lumbar spine and neck of femur: a study of 225 Caucasian women.

Rodin A, Murby B, Smith MA, Caleffi M, Fentiman I, Chapman MG, Fogelman I.

Bone. 1990;11(1):1-5.

PMID:
2331425
44.

Studies of tamoxifen in women with mastalgia.

Fentiman IS, Caleffi M, Hamed H, Chaudary MA.

Br J Clin Pract Suppl. 1989 Nov;68:34-6; discussion 49-53. Review. No abstract available.

PMID:
2488564
45.

Bone mineral content of women receiving tamoxifen for mastalgia.

Fentiman IS, Caleffi M, Rodin A, Murby B, Fogelman I.

Br J Cancer. 1989 Aug;60(2):262-4.

46.

Factors at presentation influencing the prognosis in breast cancer.

Caleffi M, Fentiman IS, Birkhead BG.

Eur J Cancer Clin Oncol. 1989 Jan;25(1):51-6.

PMID:
2920768
47.

Effect of tamoxifen on oestrogen binding, lipid and lipoprotein concentrations and blood clotting parameters in premenopausal women with breast pain.

Caleffi M, Fentiman IS, Clark GM, Wang DY, Needham J, Clark K, La Ville A, Lewis B.

J Endocrinol. 1988 Nov;119(2):335-9.

PMID:
3199064
48.

Dosage and duration of tamoxifen treatment for mastalgia: a controlled trial.

Fentiman IS, Caleffi M, Hamed H, Chaudary MA.

Br J Surg. 1988 Sep;75(9):845-6.

PMID:
3052691
49.

Osteocalcin: a potential marker of metastatic bone disease and response to treatment.

Coleman RE, Mashiter G, Fogelman I, Whitaker KD, Caleffi M, Moss DW, Rubens RD.

Eur J Cancer Clin Oncol. 1988 Jul;24(7):1211-7.

PMID:
3262063

Supplemental Content

Loading ...
Support Center